Urolog. pro Praxi, 2010; 11(6): 329-331

Oncologic results of radical retropubic prostatectomy

prostatektomie provedené na Urologické
klinice FN a LF UK v Hradci Králové

out on Urology Department of University Hospital Hradec Králové

Radical retropubic prostatectomy (RRP) is the golden standard in a management of a localized prostate cancer. In individual cases

RRP is suitable for the locally advanced prostate cancer. The authors performed the retrospective study aimed at oncologic outcomes

from 489 patients who underwent RRP in period 1998–2009. The overall, cancer-specific and PSA relaps-free was 99 %; 99.5 % and

71 %. Ninety-nine patients had positive surgical margin and 119 had biochemical relapse. Moreover 19 patients underwent adjuvant

radiotherapy for seminal vesicles infiltration or positive surgical margin. The management of biochemical relaps was in 101 patients by

salvage radiotherapy and in 18 patients by androgen-deprivation therapy. The RRP is the high effective method of a surgical treatment

of localized and in part of patients with locally advanced prostate cancer. The salvage radiotherapy or androgen-deprivation treatment

is effective treatment of the biochemical relapse.

Keywords: prostate cancer, radical retropubic prostatectomy, biochemical relapse

Published: December 14, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
provedené na Urologické P. Oncologic results of radical retropubic prostatectomy. Urol. praxi. 2010;11(6):329-331.
Download citation

References

  1. Millin T. Retropubic Urinary Surgery. London: Livingstone, 1947.
  2. Walsh PC, Donker PJ. Impotence following radical prostatectomy: Insight into etiology and prevention. J Urol 1982; 128: 492-497. Go to original source... Go to PubMed...
  3. Young HH. The early diagnosis and radical cure of carcinoma of the prostate: a study of 40 cases and presentation of a radical operation which was carried out in four cases. Johns Hopkins Hosp Bull. 1905; 16: 315-321.
  4. Gillitzer R, Thüroff JW. Relative advantages and disadvantages of radical perineal prostatectomy versus radical retropubic prostatectomy. Crit Rev Oncol Hematol. 2002; 43(2): 167-190. Go to original source... Go to PubMed...
  5. Han M, Partin AW. Nomograms for clinically localized prostate cancer. Part I: radical prostatectomy. Semin Urol Oncol. 2002; 20(2): 123-130. Go to original source... Go to PubMed...
  6. Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, Partin AW. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology. 2007; 69(6): 1095-1101. Go to original source... Go to PubMed...
  7. Van der Kwast TH, Bolla M, Van Poppel H, Van Cangh P, Vekemans K, Da Pozzo L. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 2007; 25: 4178-4186. Go to original source... Go to PubMed...
  8. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Maréchal JM, Scalliet P, Haustermans K, Piérart M. Postoperative radiotherapy after radical prostatectomy (EORTC trial 22911): A randomised controlled trial. Lancet 2005; 366: 572-578. Go to original source... Go to PubMed...
  9. Bolla M, van Poppel H, Collette L. Preliminary results for EORTC trial 22911: radical prostatectomy followed by postoperative radiotherapy in prostate cancers with a high risk of progression. Cancer Radiother 2007; 11: 363-369. Go to original source... Go to PubMed...
  10. Thompson I, Tangen C, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, Canby-Hagino E, Crawford ED. Adjuvant radiotherapy for pathologically advanced prostate cancer: A randomized Clinical Trial. JAMA 2006; 296: 2329-2335. Go to original source... Go to PubMed...
  11. Swanson GP, Hussey MA, Tangen CM, Chin J, Messing E, Cangby-Hagino E, Forman JD, Thompson IM, Crawford ED. Predominant treatment failure in postprostatectomy patients is local: Analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 2007; 25: 2225-2229. Go to original source... Go to PubMed...
  12. Wiegel T, Bottke D, Steiner U, Siegman A, Golz R, Störkel S, Willich N, Semjonow A, Souchon R, Stöckle M, Rübe C, Weissbach L, Althaus P, Rebmann U, Kälble T, Feldmann HJ, Wirth M, Hinke A, Hinkelbein W, Miller K: Phase III results of adjuvant radiotherapy (RT) versus "wait and see" (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP) (ARO 96-02/AUO AP 09/95). J Clin Oncol 2009; 27: 2924-2930. Go to original source... Go to PubMed...
  13. Hagan M, Zlotecki R, Medina C, Tercilla O, Rivera I, Wajsman Z. Comparison of adjuvant versus salvage radiotherapy policies for postprostatectomy radiotherapy. Int J Radiat Oncol Biol Phys 2004; 59: 329-340. Go to original source... Go to PubMed...
  14. Cheung R, Kamat AM, de Crevoisier R, Allen PK, Lee AK, Tucker SL, Pisters L, Babaian RJ, Kuban D. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. Int J Radiat Oncol Biol Phys 2005; 63: 134-140. Go to original source... Go to PubMed...
  15. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F. European Association of Urology. EAU guidelines on prostate cancer. Eur Urol. 2008; 53(1): 68-80. Go to original source... Go to PubMed...
  16. Buskirk SJ, Pisansky TM, Schild SE, Macdonald OK, Wehle MJ, Kozelsky TF, Collie AC, Ferrigni RG, Myers RP, Prussak KA, Heckman MG, Crook JE, Parker AS, Igel TC. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. J Urol 2006; 176: 985-990. Go to original source... Go to PubMed...
  17. Ward JF, Zincke H, Bergstralh EJ, Slezak JM, Blute ML. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognostic factor of outcome following salvage radiotherapy. J Urol 2004; 172: 2244-2248. Go to original source... Go to PubMed...
  18. Wirth MP, Hakenberg OW, Froehner M. Adjuvant hormonal treatment - the bicalutamide early prostate cancer program. Front Radiat Ther Oncol. 2008; 41: 39-48. Go to original source... Go to PubMed...
  19. Bolenz C, Gupta A, Hotze T, Ho R, Cadeddu JA, Roehrborn CG, Lotan Y. Cost comparison of robotic, laparoscopic, and open radical prostatectomy for prostate cancer. Eur Urol. 2010; 57(3): 453-458. Go to original source... Go to PubMed...
  20. Ficarra V, Novara G, Artibani W, Cestari A, Galfano A, Graefen M, Guazzoni G, Guillonneau B, Menon M, Montorsi F, Patel V, Rassweiler J, Van Poppel H. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol. 2009; 55(5): 1037-1063. Go to original source... Go to PubMed...




Urology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.